Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Withdrawn 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Hepatitis C, Chronic 3Carcinoma, Hepatocellular 2Recurrence 1Leukemia 1Hepatitis C 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 151Dexamethasone 140Rituximab 83fludarabine 78Cytarabine 69Lenalidomide 68Bortezomib 63fludarabine phosphate 62Gemcitabine 62venetoclax 54Etoposide 53pembrolizumab 52pomalidomide 48Paclitaxel 48Cisplatin 47Carboplatin 47Peripheral Blood Stem Cell Transplantation 46Filgrastim 40Radiotherapy 39Calcium Dobesilate 36Busulfan 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 29Vincristine 28Temozolomide 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Recurrence × ledipasvir × Clear all
NCT02959359 2017-08-07

DAA in the Risk of Recurrence After Curative Treatment of HCC

Taipei Veterans General Hospital, Taiwan

Phase 4 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Recurrence, Hepatitis C, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡